Arthritis, RheumatoidPhase 2NCT00550446
A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis
A Phase 2 study testing Adalimumab, CP-690-550 and CP-690,550 in people with Arthritis, Rheumatoid, run by Pfizer at 63 sites in 15 countries.
Trial summary
The purpose of this study is to determine the effectiveness and safety, over 6 months, of 5 doses of CP-690,550 for the treatment of adults with active rheumatoid arthritis. Five out of seven subjects will receive CP-690,550. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Arthritis, Rheumatoid
- What is being tested?
- Adalimumab, CP-690-550 and CP-690,550
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 386 participants
- Where
- 63 sitesin 15 countries
- Study dates
- Sep 2007to Jan 2009
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Subjects must have active rheumatoid arthritis
- Subjects must have failed at least 1 disease modifying anti-rheumatic drug (DMARD)
- Subjects must not be currently taking any DMARD other than an antimalarial
Who cannot join
- Subjects who discontinued any previous TNF inhibitor therapy for either lack of benefit or safety.
- Subjects who previously received adalimumab (Humira®) therapy for any reason.
- Subjects with evidence of blood disorders, chronic infections or untreated tuberculosis
Trial locations and contacts
63 sites in 15 countries.
63 sites in 15 countries
United States22 sites
Pfizer Investigational Site
Cedar Rapids, Iowa, 52401-2112
Pfizer Investigational Site
Dallas, Texas, 75235
Pfizer Investigational Site
Dayton, Ohio, 45408
Pfizer Investigational Site
Duncansville, Pennsylvania, 16635
Pfizer Investigational Site
Hickory, North Carolina, 28601
Pfizer Investigational Site
Hickory, North Carolina, 28602
Pfizer Investigational Site
Knoxville, Tennessee, 37909-1600
Pfizer Investigational Site
Little Rock, Arkansas, 72205
Pfizer Investigational Site
Mesa, Arizona, 85208
Pfizer Investigational Site
Mesquite, Texas, 75150
Pfizer Investigational Site
Morton Grove, Illinois, 60053
Pfizer Investigational Site
New Orleans, Louisiana, 70115
Pfizer Investigational Site
Northridge, California, 91325
Pfizer Investigational Site
Orlando, Florida, 32804
Pfizer Investigational Site
Palo Alto, California, 94304
Pfizer Investigational Site
Rockford, Illinois, 61107
Pfizer Investigational Site
Stanford, California, 94305
Pfizer Investigational Site
Tampa, Florida, 33614
Pfizer Investigational Site
Tarzana, California, 91356
Pfizer Investigational Site
Upland, California, 91786
Pfizer Investigational Site
Wichita, Kansas, 67203
Pfizer Investigational Site
Wichita, Kansas, 67208
Czechia5 sites
Pfizer Investigational Site
Brno, 656 91
Pfizer Investigational Site
Prague, 128 50
Pfizer Investigational Site
Prague, 140 59
Pfizer Investigational Site
Praha 11 - Chodov, 148 00
Pfizer Investigational Site
Zlín, 760 01
Ukraine5 sites
Pfizer Investigational Site
Kharkiv, 61000
Pfizer Investigational Site
Kyiv, 04114
Pfizer Investigational Site
Lviv, 79011
Pfizer Investigational Site
Vinnitsa, 21018
Pfizer Investigational Site
Zaporizhzhya, 69118
Bulgaria4 sites
Pfizer Investigational Site
Pleven, 5800
Pfizer Investigational Site
Sofia, 1612
Pfizer Investigational Site
Sofia, 1709
Pfizer Investigational Site
Sofia
Germany4 sites
Pfizer Investigational Site
Dresden, 01067
Pfizer Investigational Site
Hamburg, 22081
Pfizer Investigational Site
Hildesheim, 31134
Pfizer Investigational Site
Leipzig, 04103
Mexico4 sites
Pfizer Investigational Site
Cuernavaca, Morelos, 62270
Pfizer Investigational Site
Guadalajara, Jalisco, 44650
Pfizer Investigational Site
Metepec, State of Mexico, 52140
Pfizer Investigational Site
México, D.f., 06100
Chile3 sites
Pfizer Investigational Site
Providencia, Santiago, RM, 7530206
Pfizer Investigational Site
Santiago, RM, 8331030
Pfizer Investigational Site
Santiago, RM, 8360156
Romania3 sites
Pfizer Investigational Site
Bucharest, 011172
Pfizer Investigational Site
Constanța, Constanța County, 900591
Pfizer Investigational Site
Iași, Iaşi, 700661
Brazil2 sites
Pfizer Investigational Site
Porto Alegre, Rio Grande do Sul, 90035-903
Pfizer Investigational Site
São Paulo, São Paulo, 01323-903
Croatia2 sites
Pfizer Investigational Site
Split, 21000
Pfizer Investigational Site
Zagreb, 10000
Greece2 sites
Pfizer Investigational Site
Goudi, Athens, 11527
Pfizer Investigational Site
Thessaloniki, 54 636
Italy2 sites
Pfizer Investigational Site
Florence, 50139
Pfizer Investigational Site
Genova, 16132
Slovakia2 sites
Pfizer Investigational Site
Piešťany, 921 12
Pfizer Investigational Site
Žilina, 012 07
South Korea2 sites
Pfizer Investigational Site
Seoul, 110-744
Pfizer Investigational Site
Seoul, 133-792
About this study
Official title: A Phase 2b, Randomized, Double Blind, Placebo Controlled Active Comparator, Multicenter Study To Compare 5 Dose Regimens Of CP- 690,550 And Adalimumab Versus Placebo, Administered For 6 Months In The Treatment Of Subjects With Active Rheumatoid Arthritis
The purpose of this study is to determine the effectiveness and safety, over 6 months, of 5 doses of CP-690,550 for the treatment of adults with active rheumatoid arthritis. Five out of seven subjects will receive CP-690,550. One out of seven will receive adalimumab (Humira®) and one out of seven will only receive inactive substances (placebo.)
- Conditions
- Arthritis, Rheumatoid
- Being tested
- Adalimumab, CP-690-550, CP-690,550, Placebo
- Keywords
- Janus Kinase 3 Clinical Trial
- Medical subject headings
- Arthritis, Rheumatoid
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AdalimumabDrug
40mg subcutaneous injections every other week for 6 injections during week 0-10 with oral placebo BID. Subjects switched to CP-690,550 at week 12.
CP-690-550Drug
15 mg BID oral plus 6 placebo subcutaneous injections (week 0-10)
CP-690-550Drug
10 mg BID oral plus 6 placebo subcutaneous injections (week 0-10)
CP-690-550Drug
5 mg BID oral plus 6 placebo subcutaneous injections (week 0-10)
CP-690,550Drug
3 mg BID PO plus 6 placebo subcutaneous injections (week 0-10)
CP-690,550Drug
1 mg BID PO plus 6 placebo subcutaneous injections (week 0-10)
PlaceboDrug
Placebo by mouth plus 6 placebo subcutaneous injections (week 0-10)
| Study group | Role | What they receive |
|---|---|---|
| 1 | Active comparator | Not described Receives: Drug: Adalimumab |
| 2 | Experimental | Not described Receives: Drug: CP-690-550 |
| 3 | Experimental | Not described Receives: Drug: CP-690-550 |
| 4 | Experimental | Not described Receives: Drug: CP-690-550 |
| 5 | Experimental | Not described Receives: Drug: CP-690,550 |
| 6 | Experimental | Not described Receives: Drug: CP-690,550 |
| 7 | Placebo comparator | Not described Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12
ACR20 response: greater than or equal to (>=) 20 % improvement in tender joint count (TJC); >= 20% improvement in swollen joint count (SJC); and >= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).
Measured: Week 12
Secondary outcomes (30)
Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response
ACR20 response: 20% improvement in TJC; >=20% improvement in SJC; and >=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.
Measured: Week 2, 4, 6, 8, 10, 16, 20 and 24/Early Termination (ET)
Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response
ACR50 response: >= 50% improvement in TJC or SJC and 50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.
Measured: Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET
Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response
ACR70 response: >= 70% improvement in TJC or SJC and 70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.
Measured: Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET
Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response
ACR90 response: >= 90% improvement in TJC or SJC and 90% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.
Measured: Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET
Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve
ACR-n = calculated for each participant by taking the lowest percentage improvement in (1) SJC or (2) TJC or (3) the median of the remaining 5 components of the ACR response (participant's assessment of disease activity; participant's global assessment of pain; physician's assessment of disease activity; participant's assessment of physical function; an acute phase reactant value - CRP). Negative numbers indicate worsening. Area under the curve (AUC) for ACR-n is the measure of the area under the curve of the mean change from baseline in ACR-n. The trapezoidal rule was used to compute the AUC.
Measured: Baseline up to Week 2, 4, 6, 8, 10, 12
Tender Joint Count (TJC)
Number of tender joints was determined by examining 68 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1.
Measured: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET
Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET
Number of tender joints was determined by examining 68 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1. A negative value in change from baseline indicated an improvement.
Measured: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET
Swollen Joint Counts (SJC)
Number of swollen joints was determined by examination of 66 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1.
Measured: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET
Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24
Number of swollen joints was determined by examination of 66 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling = 1. A negative value in change from baseline indicated an improvement.
Measured: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET
Patient Assessment of Arthritis Pain
Participants rated the severity of arthritis pain on a 0 to 100 millimeter (mm) Visual Analog Scale (VAS), where 0 mm = no pain and 100 mm = most severe pain.
Measured: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ET
Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET
Participants rated the severity of arthritis pain on a 0 to 100 millimeter (mm) Visual Analog Scale (VAS), where 0 mm = no pain and 100 mm = most severe pain.
Measured: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET
Patient Global Assessment (PtGA) of Arthritis Pain
Participants answered: "Considering all the ways your arthritis affects you, how are you feeling today?" Participants responded by using a 0 - 100 mm VAS, where 0 mm = very well and 100 mm = very poorly.
Measured: Baseline, 2, 4, 6, 8, 10, 12, 16, 20, 24/ET
Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET
Participants answered: "Considering all the ways your arthritis affects you, how are you feeling today?" Participants responded by using a 0 - 100 mm VAS, where 0 mm = very well and 100 mm = very poorly.
Measured: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ET
Physician Global Assessment (PGA) of Arthritis
Physician global assessment of arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad.
Measured: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ET
Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET
Physician global assessment of arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad.
Measured: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ET
C-Reactive Protein (CRP)
The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. Normal range of CRP is 0 milligram per liter (mg/L) to 10 mg/L. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.
Measured: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ET
Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET
The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. Normal range of CRP is 0 mg/L to 10 mg/L. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.
Measured: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ET
Health Assessment Questionnaire-Disability Index (HAQ-DI)
HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.
Measured: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ET
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET
HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.
Measured: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ET
Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP])
DAS28-3 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) less than or equal to (<=) 3.2 implied low disease activity and greater than (>) 3.2 to 5.1 implied moderate to high disease activity, and less than (<) 2.6 = remission.
Measured: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ ET
Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET
DAS28-3 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) <= 3.2 implied low disease activity and > 3.2 to 5.1 implied moderate to high disease activity, and < 2.6 = remission.
Measured: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ ET
Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR])
DAS28-4 (ESR) calculated from SJC and TJC using 28 joint count, erythrocyte sedimentation rate (ESR) (millimeters per hour [mm/hour]) and PtGA of disease activity (transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) <= 3.2 implies low disease activity and > 3.2 to 5.1 implies moderate to high disease activity, and < 2.6 = remission.
Measured: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ ET
Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET
DAS28-4 (ESR) calculated from SJC and TJC using 28 joint count, ESR [mm/hour] and PtGA of disease activity (transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) <= 3.2 implies low disease activity and > 3.2 to 5.1 implies moderate to high disease activity, and < 2.6 = remission.
Measured: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ET
Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR)
Disease improvement was classified as good, moderate, and none based on improvement in DAS28-4 (ESR) from baseline and present DAS28-4 (ESR) score. Good: an improvement from baseline of >1.2 and a present score of <=3.2; none: an improvement of <=0.6 or >0.6 to <=1.2 with a present score of >5.1; remaining participants were classified as having moderate (Mod) improvement. Scores of good and moderate were considered to have therapeutic response.
Measured: Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ET
Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP)
CRP value less than or equal to upper limit of normal (ULN) implied disease remission (ULN=4.9 mg/L).
Measured: Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ ET
Percentage of Participants With Disease Remission Based on DAS28-3 (CRP)
DAS28-3 (CRP) defined remission was classified as a score of <2.6.
Measured: Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ ET
36-Item Short-Form Health Survey (SF-36)
SF-36 is a standardized survey evaluating 8 domains (of 2 components [C]; physical [Ph] and mental [Mn]) of functional health and well being: physical and social (So) functioning (Fn), physical and emotional role (role-physical [R-P], role-emotional [R-E]) limitations, bodily pain (BP), general health (GH), vitality (Vit), mental health (MnH). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
Measured: Baseline, Week 12, 24/ ET
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET
SF-36 is a standardized survey evaluating 8 domains (of 2 components [C]; physical [Ph] and mental [Mn]) of functional health and well being: physical and social (So) functioning (Fn), physical and emotional role (role-physical [R-P], role-emotional [R-E]) limitations, bodily pain (BP), general health (GH), vitality (Vit), mental health (MnH). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
Measured: Baseline, Week 12, 24/ ET
Euro Quality of Life 5 Dimension (EQ-5D)-Health State Profile Utility Score
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (confined to bed). Scoring formula developed by EuroQoL Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.
Measured: Baseline, Week 12, 24/ ET
Change From Baseline in Euro Quality of Life 5 Dimension (EQ-5D)- Health State Profile Utility Score at Week 12 and 24/ET
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.
Measured: Baseline, Week 12, 24/ ET
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Oct 2007 (estimated)
- Study startSep 2007
- Primary completionJan 2009
- Study completionJan 2009
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (18)Papers the sponsor has linked to this study.
- Other trials for Arthritis, RheumatoidStudies of the same condition, open and under way.
- More trials run by PfizerThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 386 participants (actual)
Sponsor and investigators
- Lead sponsor
- Pfizer
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Pfizer CT.gov Call Center, Study director, Pfizer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00550446
- Sponsor's protocol ID
- A3921035
- Status last verified
- Nov 2012
- First submitted
- 25 Oct 2007
- Last updated
- 3 Jan 2013
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Publications
Wright G, Mysler E, Roberts KD, Shelbaya A, Sweet L, Masri KR. Impact of the Sociodemographic Index on Efficacy/Safety of Tofacitinib in Patients with Rheumatoid Arthritis: Post Hoc Analysis of Phase 2/3/3b/4 Studies. Rheumatol Ther. 2026 Oct 16. doi: 10.1007/s40744-026-00881-y. Online ahead of print.
PubMed 42888330Hetland ML, Strangfeld A, Bonfanti G, Soudis D, Deuring JJ, Edwards RA. Machine learning prediction and explanatory models of serious infections in patients with rheumatoid arthritis treated with tofacitinib. Arthritis Res Ther. 2024 Aug 27;26(1):153. doi: 10.1186/s13075-024-03376-9.
PubMed 39192350Wright GC, Mysler E, Kwok K, Cadatal MJ, Germino R, Yndestad A, Kinch CD, Ogdie A. Impact of Race on the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of Pooled Clinical Trials. Rheumatol Ther. 2024 Oct;11(5):1135-1164. doi: 10.1007/s40744-024-00677-y. Epub 2024 Jul 3.
PubMed 38958913Charles-Schoeman C, Hyde C, Guan S, Parikh N, Wang J, Shahbazian A, Stockert L, Andrews J. Relationship Between Paraoxonase-1 Genotype and Activity, and Major Adverse Cardiovascular Events and Malignancies in Patients With Rheumatoid Arthritis Receiving Tofacitinib. J Rheumatol. 2023 Jul 15:jrheum.2023-0112. doi: 10.3899/jrheum.2023-0112. Online ahead of print.
PubMed 37453736Kristensen LE, Danese S, Yndestad A, Wang C, Nagy E, Modesto I, Rivas J, Benda B. Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance. Ann Rheum Dis. 2023 Jul;82(7):901-910. doi: 10.1136/ard-2022-223715. Epub 2023 Mar 17.
PubMed 36931693Hansen KE, Mortezavi M, Nagy E, Wang C, Connell CA, Radi Z, Litman HJ, Adami G, Rossini M. Fracture in clinical studies of tofacitinib in rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2022 Dec 27;14:1759720X221142346. doi: 10.1177/1759720X221142346. eCollection 2022.
PubMed 36601090Curtis JR, Yamaoka K, Chen YH, Bhatt DL, Gunay LM, Sugiyama N, Connell CA, Wang C, Wu J, Menon S, Vranic I, Gomez-Reino JJ. Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial. Ann Rheum Dis. 2023 Mar;82(3):331-343. doi: 10.1136/ard-2022-222543. Epub 2022 Dec 5.
PubMed 36600185Winthrop KL, Yndestad A, Henrohn D, Danese S, Marsal S, Galindo M, Woolcott JC, Jo H, Kwok K, Shapiro AB, Jones TV, Diehl A, Su C, Panes J, Cohen SB. Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs. Rheumatol Ther. 2023 Apr;10(2):357-373. doi: 10.1007/s40744-022-00507-z. Epub 2022 Dec 17.
PubMed 36526796Winthrop KL, Curtis JR, Yamaoka K, Lee EB, Hirose T, Rivas JL, Kwok K, Burmester GR. Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment. Rheumatol Ther. 2022 Feb;9(1):243-263. doi: 10.1007/s40744-021-00390-0. Epub 2021 Dec 6.
PubMed 34870800Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Wang L, Chen C, Kwok K, Biswas P, Shapiro A, Madsen A, Wollenhaupt J. Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. RMD Open. 2020 Oct;6(3):e001395. doi: 10.1136/rmdopen-2020-001395.
PubMed 33127856Panaccione R, Isaacs JD, Chen LA, Wang W, Marren A, Kwok K, Wang L, Chan G, Su C. Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials. Dig Dis Sci. 2021 Aug;66(8):2732-2743. doi: 10.1007/s10620-020-06560-4. Epub 2020 Aug 20.
PubMed 32816215Suzuki M, Shoji S, Miyoshi S, Krishnaswami S. Model-Based Comparison of Dose-Response Profiles of Tofacitinib in Japanese Versus Western Rheumatoid Arthritis Patients. J Clin Pharmacol. 2020 Feb;60(2):198-208. doi: 10.1002/jcph.1514. Epub 2019 Sep 12.
PubMed 31512746Mariette X, Chen C, Biswas P, Kwok K, Boy MG. Lymphoma in the Tofacitinib Rheumatoid Arthritis Clinical Development Program. Arthritis Care Res (Hoboken). 2018 May;70(5):685-694. doi: 10.1002/acr.23421. Epub 2018 Apr 2.
PubMed 28941219Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Thirunavukkarasu K, DeMasi R, Geier J, Kwok K, Wang L, Riese R, Wollenhaupt J. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis. 2017 Jul;76(7):1253-1262. doi: 10.1136/annrheumdis-2016-210457. Epub 2017 Jan 31.
PubMed 28143815Wallenstein GV, Kanik KS, Wilkinson B, Cohen S, Cutolo M, Fleischmann RM, Genovese MC, Gomez Reino J, Gruben D, Kremer J, Krishnaswami S, Lee EB, Pascual-Ramos V, Strand V, Zwillich SH. Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trials. Clin Exp Rheumatol. 2016 May-Jun;34(3):430-42. Epub 2016 Apr 28.
PubMed 27156561
Study at a glance
From the registry record, last updated by the sponsor on 3 Jan 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 2b, Randomized, Double Blind, Placebo Controlled Active Comparator, Multicenter Study To Compare 5 Dose Regimens Of CP- 690,550 And Adalimumab Versus Placebo, Administered For 6 Months In The Treatment Of Subjects With Active Rheumatoid Arthritis
- ClinicalTrials.gov ID
- NCT00550446
- Acronym / sponsor ID
- A3921035
- Conditions
- Arthritis, Rheumatoid
- Keywords
- Janus Kinase 3 Clinical Trial
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 386 participants (actual)
- Lead sponsor
- PfizerIndustry (pharma, biotech, devices)
- Study start
- Sep 2007
- Primary completion
- Jan 2009 (actual)
- Study completion
- Jan 2009 (actual)
- First posted
- 29 Oct 2007 (estimated)
- Results
- Posted 3 Jan 2013
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to determine the effectiveness and safety, over 6 months, of 5 doses of CP-690,550 for the treatment of adults with active rheumatoid arthritis. Five out of seven subjects will receive CP-690,550. One out of seven will receive adalimumab (Humira®) and one out of seven will only receive inactive substances (placebo.)
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 7
| Arm | Type | Receives |
|---|---|---|
| 1 | Active comparator | Drug: Adalimumab |
| 2 | Experimental | Drug: CP-690-550 |
| 3 | Experimental | Drug: CP-690-550 |
| 4 | Experimental | Drug: CP-690-550 |
| 5 | Experimental | Drug: CP-690,550 |
| 6 | Experimental | Drug: CP-690,550 |
| 7 | Placebo comparator | Drug: Placebo |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Subjects must have active rheumatoid arthritis
- Subjects must have failed at least 1 disease modifying anti-rheumatic drug (DMARD)
- Subjects must not be currently taking any DMARD other than an antimalarial
Key exclusion criteria (3 listed)
- Subjects who discontinued any previous TNF inhibitor therapy for either lack of benefit or safety.
- Subjects who previously received adalimumab (Humira®) therapy for any reason.
- Subjects with evidence of blood disorders, chronic infections or untreated tuberculosis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Adalimumab40mg subcutaneous injections every other week for 6 injections during week 0-10 with oral placebo BID. Subjects switched to CP-690,550 at week 12. | Drug | 1 |
| CP-690-55015 mg BID oral plus 6 placebo subcutaneous injections (week 0-10) | Drug | 2 |
| CP-690-55010 mg BID oral plus 6 placebo subcutaneous injections (week 0-10) | Drug | 3 |
| CP-690-5505 mg BID oral plus 6 placebo subcutaneous injections (week 0-10) | Drug | 4 |
| CP-690,5503 mg BID PO plus 6 placebo subcutaneous injections (week 0-10) | Drug | 5 |
| CP-690,5501 mg BID PO plus 6 placebo subcutaneous injections (week 0-10) | Drug | 6 |
| PlaceboPlacebo by mouth plus 6 placebo subcutaneous injections (week 0-10) | Drug | 7 |
Primary outcome
Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12
Time frame: Week 12
ACR20 response: greater than or equal to (>=) 20 % improvement in tender joint count (TJC); >= 20% improvement in swollen joint count (SJC); and >= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).
30 secondary outcomes
Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response
Time frame: Week 2, 4, 6, 8, 10, 16, 20 and 24/Early Termination (ET)
Percentage of Participants Achieving American College of Rheumatology 50%(ACR50) Response
Time frame: Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET
Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response
Time frame: Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET
Percentage of Participants Achieving American College of Rheumatology 90% (ACR90) Response
Time frame: Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET
Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve
Time frame: Baseline up to Week 2, 4, 6, 8, 10, 12
Tender Joint Count (TJC)
Time frame: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET
Change From Baseline in Tender Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24 or ET
Time frame: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET
Swollen Joint Counts (SJC)
Time frame: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET
Change From Baseline in Swollen Joint Count at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24
Time frame: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET
Patient Assessment of Arthritis Pain
Time frame: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ET
Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET
Time frame: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET
Patient Global Assessment (PtGA) of Arthritis Pain
Time frame: Baseline, 2, 4, 6, 8, 10, 12, 16, 20, 24/ET
Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET
Time frame: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ET
Physician Global Assessment (PGA) of Arthritis
Time frame: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ET
Change From Baseline in Physician's Global Assessment (PGA) of Arthritis Pain at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET
Time frame: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ET
C-Reactive Protein (CRP)
Time frame: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ET
Change From Baseline in C-reactive Protein (CRP) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET
Time frame: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ET
Health Assessment Questionnaire-Disability Index (HAQ-DI)
Time frame: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ET
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET
Time frame: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ET
Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP])
Time frame: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ ET
Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 10, 12, 16, 20 and 24/ET
Time frame: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ ET
Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR])
Time frame: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ ET
Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET
Time frame: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ET
Percentage of Participants With Disease Improvement Based on DAS28-4 (ESR)
Time frame: Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ET
Percentage of Participants With Disease Remission Based on Normal C-reactive Protein (CRP)
Time frame: Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ ET
Percentage of Participants With Disease Remission Based on DAS28-3 (CRP)
Time frame: Week 2, 4, 6, 8, 10, 12, 16, 20, 24/ ET
36-Item Short-Form Health Survey (SF-36)
Time frame: Baseline, Week 12, 24/ ET
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET
Time frame: Baseline, Week 12, 24/ ET
Euro Quality of Life 5 Dimension (EQ-5D)-Health State Profile Utility Score
Time frame: Baseline, Week 12, 24/ ET
Change From Baseline in Euro Quality of Life 5 Dimension (EQ-5D)- Health State Profile Utility Score at Week 12 and 24/ET
Time frame: Baseline, Week 12, 24/ ET
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Jan 2013.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 42888330Wright G, Mysler E, Roberts KD, Shelbaya A, Sweet L, Masri KR. Impact of the Sociodemographic Index on Efficacy/Safety of Tofacitinib in Patients with Rheumatoid Arthritis: Post Hoc Analysis of Phase 2/3/3b/4 Studies. Rheumatol Ther. 2026 Oct 16. doi: 10.1007/s40744-026-00881-y. Online ahead of print.
- Derived from this study: PubMed 39192350Hetland ML, Strangfeld A, Bonfanti G, Soudis D, Deuring JJ, Edwards RA. Machine learning prediction and explanatory models of serious infections in patients with rheumatoid arthritis treated with tofacitinib. Arthritis Res Ther. 2024 Aug 27;26(1):153. doi: 10.1186/s13075-024-03376-9.
- Derived from this study: PubMed 38958913Wright GC, Mysler E, Kwok K, Cadatal MJ, Germino R, Yndestad A, Kinch CD, Ogdie A. Impact of Race on the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of Pooled Clinical Trials. Rheumatol Ther. 2024 Oct;11(5):1135-1164. doi: 10.1007/s40744-024-00677-y. Epub 2024 Jul 3.
- Derived from this study: PubMed 37453736Charles-Schoeman C, Hyde C, Guan S, Parikh N, Wang J, Shahbazian A, Stockert L, Andrews J. Relationship Between Paraoxonase-1 Genotype and Activity, and Major Adverse Cardiovascular Events and Malignancies in Patients With Rheumatoid Arthritis Receiving Tofacitinib. J Rheumatol. 2023 Jul 15:jrheum.2023-0112. doi: 10.3899/jrheum.2023-0112. Online ahead of print.
- Derived from this study: PubMed 36931693Kristensen LE, Danese S, Yndestad A, Wang C, Nagy E, Modesto I, Rivas J, Benda B. Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance. Ann Rheum Dis. 2023 Jul;82(7):901-910. doi: 10.1136/ard-2022-223715. Epub 2023 Mar 17.
- Derived from this study: PubMed 36601090Hansen KE, Mortezavi M, Nagy E, Wang C, Connell CA, Radi Z, Litman HJ, Adami G, Rossini M. Fracture in clinical studies of tofacitinib in rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2022 Dec 27;14:1759720X221142346. doi: 10.1177/1759720X221142346. eCollection 2022.
- Derived from this study: PubMed 36600185Curtis JR, Yamaoka K, Chen YH, Bhatt DL, Gunay LM, Sugiyama N, Connell CA, Wang C, Wu J, Menon S, Vranic I, Gomez-Reino JJ. Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial. Ann Rheum Dis. 2023 Mar;82(3):331-343. doi: 10.1136/ard-2022-222543. Epub 2022 Dec 5.
- Derived from this study: PubMed 36526796Winthrop KL, Yndestad A, Henrohn D, Danese S, Marsal S, Galindo M, Woolcott JC, Jo H, Kwok K, Shapiro AB, Jones TV, Diehl A, Su C, Panes J, Cohen SB. Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs. Rheumatol Ther. 2023 Apr;10(2):357-373. doi: 10.1007/s40744-022-00507-z. Epub 2022 Dec 17.
- Derived from this study: PubMed 34870800Winthrop KL, Curtis JR, Yamaoka K, Lee EB, Hirose T, Rivas JL, Kwok K, Burmester GR. Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment. Rheumatol Ther. 2022 Feb;9(1):243-263. doi: 10.1007/s40744-021-00390-0. Epub 2021 Dec 6.
- Derived from this study: PubMed 33127856Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Wang L, Chen C, Kwok K, Biswas P, Shapiro A, Madsen A, Wollenhaupt J. Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. RMD Open. 2020 Oct;6(3):e001395. doi: 10.1136/rmdopen-2020-001395.
- Derived from this study: PubMed 32816215Panaccione R, Isaacs JD, Chen LA, Wang W, Marren A, Kwok K, Wang L, Chan G, Su C. Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials. Dig Dis Sci. 2021 Aug;66(8):2732-2743. doi: 10.1007/s10620-020-06560-4. Epub 2020 Aug 20.
- Derived from this study: PubMed 31512746Suzuki M, Shoji S, Miyoshi S, Krishnaswami S. Model-Based Comparison of Dose-Response Profiles of Tofacitinib in Japanese Versus Western Rheumatoid Arthritis Patients. J Clin Pharmacol. 2020 Feb;60(2):198-208. doi: 10.1002/jcph.1514. Epub 2019 Sep 12.
- To obtain contact information for a study center near you, click here.Link provided by the sponsor.
Related trials for Arthritis, Rheumatoid
Active, not recruitingObservational study
Frequency and Complications of Major Orthopedic Procedures in Medicare Beneficiaries
Rheumatoid Arthritis, Ankylosing Spondylitis
RecruitingObservational study
Characterization of Diseases With Salivary Gland Involvement
Healthy Volunteer, Sjogren's Syndrome
Not yet recruitingObservational study
Pain Phenotyping of Rheumatic Diseases - An Observational Study
Rheumatic Diseases, Lupus Erythematosus, Systemic
RecruitingPhase 2
A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE
Sjögren's Syndrome
RecruitingPhase 2
COVID-19 Booster and IIV Schedule in Immunocompromised Hosts
COVID 19, Influenza
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Pfizer CT.gov Call Center study director
Pfizer
63 sites in 15 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Adalimumab, CP-690-550 and CP-690,550 in people with Arthritis, Rheumatoid, run by Pfizer at 63 sites in 15 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Jan 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 63 sites in United States, Czechia, Ukraine, Bulgaria, Germany and 10 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 3 Jan 2013). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12 (time frame: Week 12). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00550446, which also lists 18 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Jan 2013.